The once daily tablet is expected to reach US patients in October 2026.
|Articles|August 1, 2022
A New CE Session to Check Out
A new CE opportunity that's available on-demand.
Advertisement
About The Session
Incorporating REMS Programs into the Pharmacy Process:
Risk Evaluation and Mitigation Strategy (REMS) programs can be required by the Food and Drug Administration (FDA) for medications with serious safety concerns or adverse effects. Pharmacists and pharmacy technicians need to be familiar with the mandatory components of a medication’s REMS program. Examples of mandatory REMS tasks for pharmacists and pharmacy technicians will be reviewed. Additionally, recently approved medications with REMS in 2021, as well as modified REMS programs, such as pending changes for dispensing clozapine, will be examined.
Subscription to AdvanCE required.
Advertisement
Related to this article
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
Advertisement
Advertisement